Ernexa Therapeutics (ERNAW) Total Debt (2013 - 2026)

Ernexa Therapeutics has reported Total Debt for 14 years, with the latest figure at $41000.0 in Q1 2026.

• For the quarter ending Q1 2026, Total Debt changed N/A year-over-year to $41000.0; the trailing twelve-month figure through Mar 2026 stood at $41000.0 (changed N/A YoY), and the FY2025 full-year result was $41000.0, changed N/A from the prior year.
• Total Debt for Q1 2026 stood at $41000.0, roughly flat from $41000.0 in the prior quarter.
• The five-year high for Total Debt was $4.9 million in Q3 2024, with the low at $41000.0 in Q2 2025.
• Historically, Total Debt has averaged $1.5 million across 5 years, with a median of $41000.0 in 2025.
• The largest YoY upside for Total Debt was 99.17% in 2025 against a maximum downside of 99.17% in 2025.
• Ernexa Therapeutics' Total Debt stood at $3.0 million in 2022, then fell by 14.82% to $2.5 million in 2023, then jumped by 95.63% to $4.9 million in 2024, then plunged by 99.17% to $41000.0 in 2025, then changed by 0.0% to $41000.0 in 2026.
• The last three Total Debt figures came in at $41000.0 (Q1 2026), $41000.0 (Q4 2025), and $41000.0 (Q3 2025), per Business Quant data.